Genomic Vision (Genomic) is a molecular diagnostics and technology company that develops and commercializes diagnostic tests for genetic diseases and cancers. The company’s portfolio comprises tests for breast cancer and colon cancer, diagnostic solution for facio-scapulo-humeral muscular dystrophy; and tools for identifying and characterizing rearrangements which affect the BRCA1 and BRCA2 genes. Its diagnostic tests are based on DNA molecular combing technology. Genomic’s technology finds application in monitoring both spatial and temporal characteristics of DNA replication in a single experiment and identification of structural variations at any position within the genome. It conducts research studies on large genomic rearrangements. Genomic is headquartered in Paris, France.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope
Reasons to buy
Note: Some sections may be missing if data is unavailable for the company
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Genomic Vision
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to buy
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Genomic Vision Company Overview
- Genomic Vision Company Snapshot
- Genomic Vision Pipeline Products and Ongoing Clinical Trials Overview
- Genomic Vision - Pipeline Analysis Overview
- Genomic Vision - Key Facts
- Genomic Vision - Major Products and Services
- Genomic Vision Pipeline Products by Development Stage
- Genomic Vision Ongoing Clinical Trials by Trial Status
- Genomic Vision Pipeline Products Overview
- BRCACombing Test
- BRCACombing Test Product Overview
- DNA Combing Based Test - Neurological Disorder
- DNA Combing Based Test - Neurological Disorder Product Overview
- FiberVision Automated Scanner
- FiberVision Automated Scanner Product Overview
- High-Throughput Scanner
- High-Throughput Scanner Product Overview
- HPV Combing Test
- HPV Combing Test Product Overview
- HPV Combing Test Clinical Trial
- Lynch Syndrome Test
- Lynch Syndrome Test Product Overview
- Telomere Length Assay
- Telomere Length Assay Product Overview
- Genomic Vision - Key Competitors
- Genomic Vision - Key Employees
- Genomic Vision - Locations And Subsidiaries
- Head Office
- Recent Developments
- Genomic Vision, Recent Developments
- Apr 24, 2018: Genomic Vision Invited to Present FiberVision Platform at the NIST-FDA Genome Editing Workshop in Gaithersburg (Maryland)
- Jan 17, 2018: Genomic Vision: 2017 Annual Revenue from Sales: +36% to €2.1 Million
- Oct 24, 2017: Genomic Vision: Revenue from Sales for the First 9 Months of 2017 up 103% to €1.3 Million
- Oct 18, 2017: Genomic Vision: Report of the LSR R&D Day
- Oct 11, 2017: Genomic Vision Presented the Interim Results of Its Clinical Trial in Cervical Cancer Screening at the Eurogin Annual Congress
- Sep 11, 2017: Genomic Vision: High Attendance at the 1st US Satellite Symposium on Molecular Combing
- Jul 27, 2017: Genomic Vision: Molecular Combing Featured in an Oral Presentation on CRISPR/Cas9 Gene Editing at the 3rd CSHL Meeting in New York
- Jul 25, 2017: Genomic Vision: First half 2017 results
- Jul 12, 2017: Genomic Vision: The Cologne Center for Genetics, a Major European Core Facility in Genetic Analysis, Adopts the Molecular Combing Technology
- Jun 19, 2017: Genomic Vision Inks Chinese Distribution Deal with APG Bio
- Appendix
- Methodology
- About
- Contact
- Disclaimer
List of Tables
- Genomic Vision Pipeline Products and Ongoing Clinical Trials Overview
- Genomic Vision Pipeline Products by Equipment Type
- Genomic Vision Pipeline Products by Indication
- Genomic Vision Ongoing Clinical Trials by Trial Status
- Genomic Vision, Key Facts
- Genomic Vision, Major Products and Services
- Genomic Vision Number of Pipeline Products by Development Stage
- Genomic Vision Pipeline Products Summary by Development Stage
- Genomic Vision Ongoing Clinical Trials by Trial Status
- Genomic Vision Ongoing Clinical Trials Summary
- BRCACombing Test - Product Status
- BRCACombing Test - Product Description
- DNA Combing Based Test - Neurological Disorder - Product Status
- DNA Combing Based Test - Neurological Disorder - Product Description
- FiberVision Automated Scanner - Product Status
- FiberVision Automated Scanner - Product Description
- High-Throughput Scanner - Product Status
- High-Throughput Scanner - Product Description
- HPV Combing Test - Product Status
- HPV Combing Test - Product Description
- HPV Combing Test - Association Between High-risk HPV Genome Integration Detected by Molecular Combing and Cervical Lesions Severity and/or Evolution
- HPV Combing Test - Integration of Oncogenic HPV DNA in Czech Republic
- Lynch Syndrome Test - Product Status
- Lynch Syndrome Test - Product Description
- Telomere Length Assay - Product Status
- Telomere Length Assay - Product Description
- Genomic Vision, Key Employees
- Glossary
List of Figures
- Genomic Vision Pipeline Products by Equipment Type
- Genomic Vision Pipeline Products by Development Stage
- Genomic Vision Ongoing Clinical Trials by Trial Status
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Qiagen Marseille SA
- Adocia SAS
- Genfit SA
- IntegraGen SA
